Change Visitor Type



Oxford Capital exited its investment in Sirigen in August 2012. Sirigen was acquired by Becton, Dickinson and Company, a leading global medical technology company for $65 million.

Sirigen commercialised a novel application of conducting polymers in the medical diagnostics market. Sirigen’s technology adds “high sensitivity fluorescence” (HSF) to diagnostic techniques, as well as simplifying sample processing and instrumentation requirements. Generating sufficient signal from diagnostic tests, in order to be sure of an accurate diagnosis, is a key challenge for the diagnostic industry. By incorporating the light-harnessing power of the Sirigen polymers, the signal from the diagnostic is greatly increased.

  • The Times – The best online investment providers for 2019

    Read more
  •’s Connotate recognized in ‘100 Companies That Matter in Knowledge Management 2019’ list

    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • Review: I see You is “a beautifully crafted puzzle of a horror movie”

    Read more
  • UltraSoC demonstrates advanced multicore debug at Embedded World 2019

    Read more
  • UltraSoC announces support for Western Digital RISC-V SweRV Core and OmniXtend cache-coherent interconnect

    Read more